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Volume 51, Number 11S Abstracts 35SResults: 83men (76.9%) and 25 women (23.1%), with a
mean age of 72.9 years, underwent open type IV TAAA
repair. Nine patients (8.3%) were ruptured. Mean aneurysm
maximal diameter was 6.5  1.3 cm. Supraceliac and left
kidney ischemia were 22.9  9.3 and 40.6  16.2 minutes,
respectively. Mean blood loss was 2.5 liters. 6 patients (5.9%)
died at 30 days; of these one was ruptured preoperatively. No
preoperative or intraoperative factor predicted early mortality.
Major complication rate was 25.9% (n  28). Patients with
symptomatic aneurysms were predisposed tomajor complica-
tion (p  .029). Six patients (5.9%) required initiation of
long-term dialysis; this was associated with preoperative creat-
inine clearance  37 mL/min (p  .041). In order to assess
the effect of left renal artery bypass (LRAB) on patient out-
come, comparison was made to 50 patients who underwent
pararenal AAA (PRAAA) repair with supraceliac clamping but
without LRAB (Table 1).
Conclusions:Ourexperiencedemonstrates thatopen type
IV TAAA repair can be performed with relatively lowmorbidity
and mortality. In addition, type IV TAAA and PRAAA repairs
had comparable morbidity and mortality, suggesting that the
morbidity of type IVTAAA repair is due to supraceliac ischemia.





(n  50) P-value
Ruptured aneurysm 9 (8.3%) 6 (12%) 0.66
Duration of supraceliac
ischemia (min)
22.9  9.3 21.3  7.9 0.33
Duration of left renal
artery ischemia (min)
40.3  16.2 21.2  7.8 0.001
Mortality 6 (5.6%) 4 (8%) 0.814
Major complication 28 (25.9%) 12 (24%) 0.950
Long-term hemodialysis 6 (5.9%) 0 (0%) 0.198
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Objectives: Thoracic endograft collapse after thoracic
endovascular aortic repair (TEVAR) is a potentially devas-
tating complication. This study aims to evaluate the man-
agement of thoracic stent graft collapse.
Methods: A multicenter review was performed from
2005-2009. Diagnosis and preoperative planning was per-
formed by CT angiography. Outcome measures included
the success of endovascular salvage, postoperative compli-
cations and conversion to open repair.Results: 12 cases of endograft collapseweremanaged in11
patients, 10 males and 1 female. Mean age was 41.2 (range,
21-66 years). 8 had aortic transections. 3 had type B dissections.
All were initially treated with TAG endografts (W. L Gore,
Flagstaff, AZ). All collapses were treated by redo TEVAR. The
median duration from initial repair to collapsewas 9 days (range,
1-1126days).Highradial forcedeviceswereused in5casesusing
Talent thoracic stent grafts (Medtronic, Santa Rosa, CA) in 3
cases and Palmaz stents (Cordis, Miami, FL) in 2 cases with
re-expansion of all 5 grafts. TAG endografts were used in 7 cases
with re-expansion of 6 grafts. The persistent collapse was man-
aged with a Palmaz stent. This was complicated by an iatrogenic
type A dissection. The overall complication rate with re-grafting
using TAG endografts was 43%. Late complications following
redo TEVAR included an aortoesophageal fistula and persistent
physiologic coarctation, which were both treated by open con-
version. 2 additional patients underwent open conversion; 1 for
an aforementioned type A dissection, and another elective con-
version toprevent a recurrent collapse fromseverebird’sbeaking.
The overall open conversion rate was 36%.
Conclusions: Stent graft collapse can be effectively
and safely managed by endovascular techniques. Redo
TEVAR using high radial force devices should be con-
sidered the initial treatment of choice. Based on this case
series, failed endovascular salvage of collapsed en-
dografts can successfully be managed with open repair
without added mortality.
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Reanastomosis of Divided Left Renal Vein During Aneu-
rysm Repair Is Not Necessary
Sachinder Hans. Henry Ford Macomb, Warren, MI
Objectives: To assess the functional status of kidneys
and determine if reanastomosis of the left renal vein
(RLRV) provides any advantage over ligation of left renal
vein (LLRV).
Methods: Three hundred eighty four patients under-
went abdominal aortic aneurysm repair (AAA) from 1999 to
2009. Twenty-six patients (6.8%) had juxtarenal AAAs and 24
required division of the left renal vein. In ten out of those 24,
RLRV was performed. Patency of the anastomosed left renal
vein was confirmed by intraoperative duplex scan. The re-
maining 14 patients underwent LLRV medial to adrenal and
gonadal veins. Preoperative creatinine clearance (Cockroft-
Gault equation) was compared in both groups at postopera-
tive day seven and at long-term follow-up. All patients in the
LLRV group underwent either nuclear scan (n9) or CT an-
giography (n5) for assessment of functional status of each
kidney at long-term follow-up.
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Conclusions: Reanastomosis of the divided left renal
vein undergoing AAA repair does not provide any long-
term advantage over ligation in patients with either normal
or slightly abnormal preoperative renal function.
Comparison of patient characteristics between groups.
RLRV (n10) LLRV (n14) P-value
Age (Mean  SD) 70  4.0 69.5  10.9 ns
Gender (% male) 80% (8) 85.7% (12) ns
DM 10% (1) 14.4% (2) ns
HTN 60% (6) 64.4% (9) ns
CAD 40% (4) 57.1% (8) ns
Nicotine Abuse 100% (10) 92.9% (13) ns
Diameter of Aneurysm 7.0  1.8 6.8  1.3 ns
Preoperative Creatinine 1.3  0.47 1.2  0.36 ns
Creatinine Clearance 66.1  19.8 82.8  40.1 ns
Site of Cross-Clamping
Interrenal 70% (7) 33.3% (4)
Suprarenal 30% (3) 66.7% (10)










48  4 months/mL)
RLRV 66.1  19.8 41.9  27.0 47.1  20.2
LLRV 82.8  40.1 73.9  37.9 61.9  38.9
P-value  ns
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Objectives: The CardioMEMS EndoSure wireless
pressure sensor has been used to ensure exclusion of the
aortic sac during endovascular aortic repair (EVAR). How-
ever, little has been studied regarding the impact of the
pressure sensor on longitudinal axial imaging studies.
Methods: 79 patients underwent EVAR with implanta-
tion of the EndoSure device. All patients had post exclusion
sensor readings taken at the time of operation. All follow-up
visits were accompanied by EndoSure sensor reading and CT
scan. A total of 205 readings were matched with concurrent
CT scan for evaluation of aortic sac size and presence of
endoleak. Exclusion of the sacwas defined by a reduction of at
least 30% in either systolic or pulse pressure. Patients whose
sensor readings signaled non-exclusion were analyzed by uni-
variate analysis. Significance was set at p 0.05.
Results: Seventy-nine patients had complete data. The
group was 79.5% male, had an average age of 74.5  8.8
years and an average AAA diameter of 5.59  0.9 cm.
Twenty four of 79 patients had a EndoSure reading which
signaled non-exclusion of the aortic sac. Of these, four hada CT-verified type I or III endoleak. Overall the sensitivity
was 0.90 and the specificity was 0.31 for exclusion of the
sac. The positive predictive value was 0.95 and the negative
predictive value was 0.16. Patients with false negatives for
sac exclusion were significantly younger than those who
had a type I or III endoleak (71.6 1.7 vs 79.5 2.7, p
0.05). Also, male patients were significantly higher in false
negatives than in true type I or III endoleaks (85% vs 25%,
p  0.01). No other variables were significantly different
between groups. If EndoSure had been used as the sole
diagnostic test, it would have triggered 20 unnecessary CT
scans.
Conclusions:CardioMEMSEndoSurehas ahigh sensitiv-
ity andpositivepredictive value fordetecting sac exclusion.How-
ever, its high negative predictive value may lead to unnecessary
tests. This tends to affect younger andmale patients more often.
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Intensive Statin Therapy Is Associated With a Decrease
in Adverse Events and Death Following Carotid Revas-
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Catherine K. Chang1, Chetan P. Huded2, Philip P. Good-
ney1, Brian W. Nolan1, Daniel B. Walsh1, Richard J. Pow-
ell1. 1Vascular Surgery, Dartmouth Hitchcock Medical
Center, Lebanon, NH; 2Dartmouth Medical School,
Hanover, NH
Objectives: To determine whether high dose statin
therapy is associated with a reduction in major adverse
events when compared to low/moderate dose or no statin
therapy following carotid revascularization.
Methods: A retrospective review was performed of 872
consecutive carotid endarterectomy (CEA) and carotid artery
stenting (CAS) procedures in 804 patients between 1/2003
and 3/2009. Patient demographics, co-morbidities, and clin-
ical outcomes were collected. High dose statin therapy was
defined as atorvastatin, simvastatin, pravastatin, lovastatin, or
fluvastatin at 80 mg/day or rosuvastatin at 20 mg/day start-
ing before or at time of procedure. The composite primary
outcome measure was all-cause mortality, stroke, any reinter-
vention, and recurrent stenosis 70% at 5 years. Statistical
analysis utilized a multivariate logistic regression model.
Results: At time of carotid revascularization, 216 pa-
tients were on no statin, 548 on a low or moderate dose, and
108 on a high dose statin. Hypertension, diabetes, coronary
artery disease, peripheral arterial disease, and congestive heart
failure were all significantly more prevalent in the high dose
group.Highdose statinswere associatedwith a decrease in the
composite endpoint from 19% to 11% (p  0.05) compared
